Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

I-SPY Graduates: Where Are They Now?

Executive Summary

Five neoadjuvant breast cancer regimens have been tested successfully in I-SPY Phase II program, but three have not moved on to sponsor-driven pivotal testing and the I-SPY 3 master protocol has yet to be used.

Advertisement

Related Content

Master Protocols In Practice
Puma's Neratinib SUMMIT Study Shows Potential & Pitfalls Of Precision Medicine
Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol
I-SPY 2 Helping To Normalize Adaptive Trial Designs
After ALTTO: I-SPY Will Hold More Clues About pCR Surrogate Endpoint
Failed ALTTO Breast Cancer Trial Casts Doubt On pCR Marker
Life After I-SPY Graduation: Neratinib Likely To Be Tested With Roche’s Perjeta
Roche’s Master Plan: Perjeta Gains Early Breast Cancer Approval, Late-Stage Kadcyla Data

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS118731

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel